Expression Levels of EZH2 and KMT2D in Patients with Diffuse Large B-Cell Lymphoma and Their Relationship with Pathological Features.
10.19746/j.cnki.issn.1009-2137.2025.03.021
- Author:
Peng PENG
1
;
Wen-Rong ZOU
1
;
Yang-Lu BAI
1
;
Yan GUO
1
;
Ning ZHOU
2
;
Xue-Jia FENG
1
Author Information
1. Department of Hematology,Mianyang 404 Hospital, Mianyang 621000, Sichuan Province, China.
2. Department of Pathology, Mianyang 404 Hospital, Mianyang 621000, Sichuan Province, China.
- Publication Type:Journal Article
- Keywords:
EZH2;
KMT2D;
diffuse large B-cell lymphoma;
pathological feature
- MeSH:
Humans;
Enhancer of Zeste Homolog 2 Protein/metabolism*;
Lymphoma, Large B-Cell, Diffuse/metabolism*;
DNA-Binding Proteins/metabolism*;
Female;
Male;
Middle Aged;
Adult;
Neoplasm Proteins/metabolism*;
Aged;
Immunohistochemistry;
Proto-Oncogene Proteins c-bcl-6/metabolism*;
Prognosis
- From:
Journal of Experimental Hematology
2025;33(3):769-776
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression levels of EZH2 and KMT2D in patients with diffuse large B-cell lymphoma (DLBCL) and their relationship with pathological features.
METHODS:84 patients with DLBCL treated in our hospital from January 2021 to June 2022 were selected as the study subjects, and clinical characteristics such as sex, age and pathological classification of the patients were collected. Immunohistochemistry was used to detecet the expression of KMT2D and EZH2 proteins in tumor tissue cells of the DLBCL patients. The differential expression of KMT2D and EZH2 in subgroups of different sexes, ages, primary sites, clinical stages, Hans subtypes, etc. were compared. The correlation between the expression of KMT2D and EZH2 protein and BCL-6, CD79A was analyzed and validated through the interaction of protein molecular structures. We followed up and recorded the survival status of the patients for 12 months, and analyzed the factors that affect the mortality of DLBCL patients.
RESULTS:The positive rate of KMT2D and EZH2 was high (over 95%) in DLBCL patients. There was no significant difference in the expression of EZH2 and KMT2D among subgroups of different sexes, ages and stages (P >0.05). However, patients with different levels of BCL-6 and CD79A expression showed differences in EZH2 and KMT2D expression (P < 0.05). EZH2 and KMT2D were positively correlated with BCL-6 (r =0.391, r =0.332) and CD79A (r =0.309, r =0.258), respectively, and there were interactions in the protein molecular structures. The risk factors for mortality in DLBCL patients include male sex (OR =1.106, 95%CI : 1.082-1.130, P < 0.001), stage II (OR =1.778, 95%CI : 1.567-2.016, P < 0.001), stage IV (OR =2.233, 95%CI : 2.021-2.467, P < 0.001), EZH2 positive (OR =2.762, 95%CI : 1.304-5.850, P =0.008), BCL-6 positive (OR =7.309, 95%CI : 1.340-39.859, P =0.022), age≥74 years (OR =3.080, 95%CI : 1.658-5.723, P < 0.001), and 63-73 years old (OR =2.400, 95%CI : 1.564-3.682, P < 0.001), while KMT2D positive (OR =0.180, 95%CI : 0.054-0.608, P =0.006) and 41-51 years old (OR =0.406, 95%CI : 0.274-0.603, P < 0.001) were factors which could reduce the risk of mortality.
CONCLUSION:EZH2 and KMT2D are highly expressed in patients with DLBCL, and they are positively correlated with BCL-6 and CD79A, and affect the prognosis of DLBCL patients.
